Psoriasis Withdrawn: Linked to Brain Disease

A subsidiary Swiss drug maker of Roche Holding AG has announced a phased market withdraw of the injectable, psoriasis treatment drug, Raptiva because of Raptiva’s link to a deadly brain disease. Genentech Inc. announced that at least three patients have been infected with the brain infection progressive multifocal leukoencephalopathy (PML) since October.

RAPTIVA is supplied as a sterile, white to off-white, lyophilized powder in single-use glass vials for subcutaneous (SC) injection. Reconstitution of the single-use vial with 1.3 mL.

Contact Information